In clinical trials
Digestive & weight
Apraglutide
Evidence
Clinical trials
Class
Long-acting GLP-2 receptor agonist
KEY TAKEAWAY
Apraglutide is a long-acting GLP-2 analog designed for once-weekly dosing. It is being developed for short bowel syndrome. Apraglutide is not FDA-approved and has been tested in late-stage clinical trials.
Written by the Veylo editorial team · Updated
November 2026
What it is
Long-acting GLP-2 receptor agonist
Being studied for
Studied in short bowel syndrome with intestinal failure
Key fact
Apraglutide is not FDA-approved and has been tested in late-stage clinical trials.
Route
Weekly subcutaneous injection in trials
Evidence strength
Clinical trials
Apraglutide is a long-acting GLP-2 analog designed for once-weekly dosing. It is being developed for short bowel syndrome.
It activates GLP-2 receptors to support growth of the intestinal lining and improve absorption.
Apraglutide is not FDA-approved and has been tested in late-stage clinical trials.
Studied in short bowel syndrome with intestinal failure.
Reported effects include abdominal pain, swelling and nausea. Growth of the gut lining requires monitoring.
Apraglutide: see PubMed and ClinicalTrials.gov for published studies and registered trials. No FDA drug label exists for the uses described.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.